ewsba.se
Tenet reported Q1 net operating revenues of $5.4 billion and consolidated adjusted EBITDA of $1.16 billion (21.6% margin), beat prior expectations, generated $978 million of adjusted free cash flow, held $2.97 billion cash, repurchased 1.35 million shares for $318 million, and reaffirmed full‑year 2026 guidance.
Segment results were mixed but strong overall: USPI posted adjusted EBITDA of $484 million (36.7% margin) with 5.3% same‑facility revenue growth, while hospitals delivered $678 million of EBITDA (16.7% margin) with modest inpatient admission growth offset by a 41% drop in respiratory cases.
Management highlighted payer‑mix headwinds—exchange admissions down about 10% and exchange revenues down roughly 9–10% YoY, plus some Medicaid softness—while pushing a strategy toward higher‑acuity care and AI/process automation pilots to improve throughput and reduce costs.
Interested in Tenet Healthcare Corporation? Here are five stocks we like better.
Top Analyst-Rated Healthcare Stocks to Watch Now
Tenet Healthcare (NYSE:THC) reported first-quarter 2026 net operating revenues of $5.4 billion and consolidated adjusted EBITDA of $1.16 billion, for an adjusted EBITDA margin of 21.6%, as management cited disciplined expense execution, stable volumes despite coverage-related headwinds, and strong free cash flow generation.
Chairman and CEO Dr. Saum Sutaria said results came in “above our previously provided expectations,” even as the company navigated “payer mix shifts, seasonal effects, and insurance enrollment uncertainty in the exchanges and Medicaid that impact demand.” CFO Sun Park said operating expense performance benefited from progress on initiatives discussed in the prior quarter and contributed to the margin outcome.
→ Corning Beats Q1 Estimates but Drops 9% on Guidance Miss
In the ambulatory segment, USPI generated adjusted EBITDA of $484 million, up 6% from the first quarter of 2025, with an adjusted EBITDA margin of 36.7%. Sutaria said USPI posted “a robust 22%” of full-year 2026 adjusted EBITDA guidance in the first quarter, and noted a recent pattern of earnings shifting modestly toward the first quarter.
USPI same-facility system-wide revenues grew 5.3% year over year. Park said net revenue per case increased 5.6% while same-facility case volumes declined 0.3%, with volumes impacted by winter storms. Sutaria said teams were able to reschedule many procedures, “lessening the overall impact in the quarter,” and also referenced uncertainty stemming from vendor cyberattacks.
→ Meta Posted Its Best Sales Growth Since 2021—So Why Did Shares Fall?
HCA Healthcare: Temporary Setbacks, Long-Term Strength
Tenet’s hospital segment produced adjusted EBITDA of $678 million and a 16.7% margin, which management said exceeded expectations and represented 27.5% of full-year hospital adjusted EBITDA guidance. Park said same-hospital inpatient adjusted admissions rose 0.6% but were affected by a 41% decline in respiratory admissions versus the prior-year quarter, which reduced admissions growth by 90 basis points.
Revenue per adjusted admission declined 1.5% year over year, which Park attributed to reduced exchange volumes within the payer mix and the year-over-year effect of $40 million in favorable out-of-period supplemental Medicaid revenues recorded in the first quarter of 2025.
→ Verizon’s Signal Strength: The Turnaround Call Is Loud and Clear
Management discussed ongoing uncertainty tied to exchange coverage and Medicaid trends. Sutaria said same-store exchange admissions were down about 10% compared with the first quarter of 2025, though “not yet at the level we assumed as the average for the full year.” Park added that exchange revenues represented about 6% of consolidated revenues in the quarter, down from about 6.5% in the first quarter of 2025, which he characterized as roughly a 9% to 10% decline year over year.
In response to analyst questions about denials, Park said payer disputes that can result in denials “are high” and “too high” compared with pre-pandemic periods, but he did not see a meaningful change in net impact this quarter versus last year. On uncompensated care, Sutaria said the company could “only guess” that “some of it has to do with the expiration of the exchange subsidies.”
On Medicaid, Sutaria said Medicaid was “down a little bit,” with more of that decline visible in places like California, suggesting some disenrollment or lack of renewal. He also said Tenet has observed “a little bit of hesitation” among certain populations in markets where it partners with federally qualified health centers, though he characterized the impact on hospitals as “minimal” while noting more effect on outpatient primary care utilization.
Sutaria emphasized both segments’ focus on higher-acuity care. At USPI, he highlighted double-digit same-store volume growth in total joint replacements performed in ambulatory surgery centers and pointed to expanding service lines such as urology and robotics. He said USPI has more than 150 robotic surgery programs in ASCs that are general surgery-based and described declines mainly in “high volume, low acuity” services.
In hospitals, Sutaria said Tenet has spent five years pushing a high-acuity strategy—supported by transfer centers, new surgical programs, and emergency-related services such as trauma programs—while also working to reduce length of stay to preserve capacity. He told analysts that throughput and length-of-stay management are “intricately linked” to supporting high-acuity demand and can help with “capital avoidance on additional capacity.”
The company also detailed broader efficiency initiatives, including technology and AI-related tools. Sutaria cited engagement tools for recruitment and retention, process automation targeting length of stay, and capacity controls to improve clinical throughput. He described pilots involving EMR-integrated tools—such as Ambient Scribe, automated discharge summaries, and autonomous professional fee coding—and said back-office AI automation has improved productivity and reduced third-party spending, noting that Tenet has “almost doubled or more the productivity” of the Conifer analytics team. He added that governance is used to either scale successful pilots rapidly or shut down those that do not work.
Tenet generated $978 million of adjusted free cash flow in the first quarter. As of March 31, 2026, the company had $2.97 billion of cash on hand and no borrowings under its credit facility, Park said, and it had no significant debt maturities until late 2027. The leverage ratio was 2.24x EBITDA, or 2.83x EBITDA less noncontrolling interests, according to Park.
During the quarter, Tenet repurchased 1.35 million shares for $318 million. Sutaria said the company continues to see “significant opportunity to utilize share repurchase at our current valuations,” and Park said share repurchases remain part of capital deployment priorities alongside USPI M&A, hospital growth investments, and evaluating opportunities to retire or refinance debt.
USPI growth investments were also a focal point. Sutaria said Tenet invested $125 million in the first quarter to acquire seven ASCs and began patient care at three de novo centers, representing “half of our targeted full-year spend already completed in the first quarter.” He also said USPI has “a robust pipeline” of assets interested in joining this year and argued Tenet’s track record, operational expertise, and partner relationships support its position as an acquirer of choice.
Management reaffirmed full-year 2026 guidance, saying it was too early to adjust despite first-quarter outperformance. Park said the outlook excludes contributions from any potential increases in supplemental Medicaid programs not yet approved and finalized by CMS. For the second quarter, Park said consolidated adjusted EBITDA is expected to be 24% to 25% of full-year adjusted EBITDA at the midpoint, with USPI similarly expected to be 24% to 25% of full-year USPI EBITDA at the midpoint.
For the full year, Tenet expects adjusted free cash flow after noncontrolling interests of $1.6 billion to $1.83 billion, including about $150 million of tax payments related to the Conifer transaction. Park said excluding those tax payments, the midpoint would imply $1.865 billion of adjusted free cash flow after noncontrolling interests.
Separately, Park noted Tenet recognized a one-time approximately $40 million favorable revenue adjustment tied to the completed Conifer transaction in the first quarter, which he said was included in original guidance and excluded from revenue per adjusted admission calculations. The company recorded supplemental Medicaid revenues of $304 million in the quarter, consistent with guidance assumptions, and Park emphasized there were no out-of-period supplemental Medicaid revenues related to prior years in the first quarter of 2026.
Tenet Healthcare Corporation (NYSE: THC) is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet's operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.
In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.
The article "Tenet Healthcare Q1 Earnings Call Highlights" was originally published by MarketBeat.